Simple Summary There are currently no blood biomarkers approved for routine clinical use
in endometrial cancer. Serum human epididymis protein 4 (HE4) is significantly higher in …

Endometrial cancer is the most common malignancy of the female genital tract and its
incidence is rising in parallel with the mounting prevalence of obesity. Early diagnosis has …

One emerging problem for onco-gynecologists is the incidence of premenopausal patients
under 40 years of age diagnosed with stage I Endometrial Cancer (EC) who want to …

Endometrial cancer is the leading gynaecological malignancy in the western world and its
incidence is rising in tandem with the global epidemic of obesity. Early diagnosis is key to …

Abstract HE4 (human epididymis protein 4) is overexpressed in both ovarian and
endometrial cancers. Levels of the shed HE4 protein are elevated in sera from ovarian and …

Abstract Human epididymis protein 4 (HE4) has received major attention as a potential
tumor marker in epithelial ovarian cancer; however, evidence of significant overexpression …

Despite the improvement in overall survival for ovarian cancer (OC) patients, a fraction of
patients with advanced-stage disease fails to respond to primary therapy and relapses in …

Objective To evaluate whether human epididymis protein 4 (HE 4) and CA 125 correlate
with known high‐risk prognostic factors for endometrial cancer. Design Prospective …

Introduction: Endometrial cancer is the most frequent gynecological malignancy in the
developed world. Currently, endometrial histology is the gold standard for diagnosis, as …

OBJECTIVE: Optimal surgical outcome has been proved to be one of the most powerful
survival determinants in the management of ovarian cancer patients. Actually, for ovarian …